: Revolution Medicines started at hold with $34 stock price target at Stifel Nicolaus

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Revolution Medicines Inc.

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply